Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children
| Status: | Recruiting |
|---|---|
| Conditions: | Other Indications, Other Indications |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any - 18 |
| Updated: | 3/9/2019 |
| Start Date: | March 6, 2019 |
| End Date: | March 2021 |
| Contact: | Mary Elizabeth Davis, MSN, RN, AOCNS |
| Email: | davism@mskcc.org |
| Phone: | 212-639-3147 |
Determination of Hearing Status in Children Receiving Intra-Arterial Carboplatin for Intraocular Retinoblastoma
The purpose of this study is to find out how often hearing loss occurs in patients with
retinoblastoma after receiving treatment with intra-arterial carboplatin.
retinoblastoma after receiving treatment with intra-arterial carboplatin.
Inclusion Criteria:
- Signed informed consent indicating awareness of the investigational nature of the
protocol.
- Children with RB aged 3 months and older who are scheduled to receive their first dose
of IA carboplatin chemotherapy.
- Retinoblastoma is rarely seen in children over 8 years old, however we will not
include an upper age range so as not to exclude any possible participants
Exclusion Criteria:
- Children with known and documented preexisting hearing loss.
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 212-639-3147
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
